Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14374808 | 0.90 | PLG (0.36) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL2367323 | 0.90 | MDM2 (0.42) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL29469785 | 0.90 | MDM2 (0.42) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL2366956 | 0.90 | MDM2 (0.42) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL4430880 | 0.89 | CASP3 (0.39) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL8961420 | 0.85 | KMT2A (0.38) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL2366962 | 0.85 | PLG (0.37) | PLGF10PLAUKLKB1KMT2A | |
| SCHEMBL2367324 | 0.85 | PLG (0.37) | PLGF10PLAUKLKB1KMT2A | |
| SCHEMBL8260151 | 0.85 | PLG (0.34) | PLGF10PLAUKLKB1CASP3 | |
| SCHEMBL12214883 | 0.85 | PLG (0.34) | PLGF10PLAUKLKB1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | PLG 658/4885F10 755/4885PLAU 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.